Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daratumumab, Cyclophosphamide, Dexamethasone +/- Pomalidomide in RRMM
NCT03215524Phase 2Completed
- Sponsor
- Canadian Myeloma Research Group
- Start
- Oct 2017
- Primary completion
- Jun 2022
- Modality
- Molecular Glues
- Countries
- 1
01
Overview
A Phase 2 trial of pomalidomide in multiple myeloma (MM), sponsored by Canadian Myeloma Research Group. Started Oct 2017; status: completed.
02
Drugs
pomalidomide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT03215524.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03215524.